Differential antiatherogenic effects of PPARα versus PPARγ: Agonists should we be surprised?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 9, 2005, Pages 1763-1764

  Camejo, Germán ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; AMINO ACID; APOLIPOPROTEIN E2; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLUCAGON; GLUCOSE; GLYCOGEN; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN; HYDROCORTISONE; INSULIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; EDITORIAL; ENERGY METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ATHEROSCLEROSIS; CLOFIBRIC ACID; HUMANS; HYPOGLYCEMIC AGENTS; PPAR ALPHA; PPAR GAMMA;

EID: 24144463124     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000181034.54148.8d     Document Type: Editorial

References (14)

1. Kersten S, Desvergene B, Wahli W. Roles of PPARS in health and disease. Nature. 2000;405:421-424.
2. Francis G, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Ann Rev Physiol. 2003;65:261-311.
3. Fazio S, Linton M. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Ather Rep. 2004;6: 148-157.
4. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsue W, Law R. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arteriocler Thromb Vasc Biol. 2001;21:365-371.
5. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T, Tamura Y, Okazaki H, Yahagi N, Iizuka Y, Shionoiri F, Ohashi K, Harada K, Shimano H, Nagai R, Yamada N. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arteriocler Thromb Vasc Biol. 21:372-377.
6. Li A, Brown K, Silvestre M, Wilson T, Palinski W, Glass K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-defcient mice. J Clin Invest. 2000;106: 523-531.
7. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J Clin Invest. 2004;114:1564-1576.
8. Sidhu J, Kaposzta Z, Markus H, Kaski J. Effect of rosiglitazone on common carotid intima-media thickness in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol. 2004; 24:930-943.
9. Langenfeld MR, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, Füllert SD, Sachara C, Pfützner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation. 2005;111:2525-2531.
10. Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fievet C. PPARα, but not PPARγ, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2005;25:1897-1902.
11. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse apoE with human ApoE 2. J Clin Invest. 1998; 102:130-135.
12. Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quafordt SH, Sullivan PM, Maeda N. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 1999;103: 1579-1586.
13. Mahley R, Ji Z-S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40:1-16.
14. Olsson U, Egnell AC, Rodriguez M, Östergren G, Lorentzon M, Salmivirta M, Bondjers G, Camejo G. Changes in matrix proteoglycans induced by insulin and fatty acids in hepatic cells may contribute to dyslipidemia of insulin resistance. Diabetes. 2001;50:2126-2132.